Panacea Biotec is trading up 19% at Rs 221 after the company announced that it has been awarded financial assistance of Rs 10 crore from the Government of India for development of pandemic influenza vaccine, in the form of a long-term loan on concessional rate of interest of 2% p.a.
The company recently signed an agreement with Department of Biotechnology (DBT) in this regard and has received the first installment of Rs 3 crore.
“This grant of financial assistance by Government of India through DBT is in addition to the grant of Advance Market Commitment (AMC) of Rs 10 crore given to the company by Ministry of Health & Family Welfare (MoHFW), Govt. of India to encourage development, manufacture and supply of the said vaccine of paramount national importance” the company said in a filing to the stock exchange.
The stock opened at Rs 188 on the BSE and has touched a high of Rs 222 thus far, with 70,000 equity shares changing hands on the counter.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app